キメラ抗原受容体T細胞療法（CART）の世界市場...市場調査レポートについてご紹介

1 Report Introduction 3

2 Executive Summary Snapshot 9

3 Executive Summary 10

4 Introduction 12
4.1. Chimeric antigen receptor (CAR) T-cells 12
4.2. History 12
4.3. CARs and Generations 12
4.4. Advantages of CAR-T cells 17
4.5. Adverse Events with CAR T-cell Therapy 17

5 CAR-T CELL THERAPY-ANALYSIS 18
5.1. CAR-T Collaboration Deals 18
5.1.1. CAR-T Cells Therapy Collaborations and Deal Year 18
5.1.2. Collaborations & Deal Value Trends 20
5.1.3. Companies collaborations for future developments 22
5.2. CAR-T Acquisitions Deals 24
5.2.1. CAR-T Cells Therapy Acquisitions Trends 24
5.2.2. CAR-T Cells Therapy Acquisitions Offerings by Big Giants 25
5.3. New facility for the development of CAR-T cells 26
5.4. CAR-T Licensing Opportunities 27
5.5. Pipeline Scenario 28
5.5.1. Pipeline Products under Development-An Overview 28
5.5.2. Pipeline Products under Development by Company 29
5.5.3. CAR T-cells Therapeutic Areas & Companies 31
5.5.4. CAR-T cells Targeted Antigens 34
5.5.5. CAR-T Therapies-Clinical trials & Completion Year 37
5.5.6. CAR T-cell Technologies & Companies Involved 39
5.5.7. CAR-T Safety Switches & Company involved 41

6 PIPELINE PROFILES 42

7 Market Drivers 111

8 Market Barriers 113

9 SWOT Analysis 115

10 Report Methodology 116

11 Consulting Services 118

List of Tables
Table 1: CARs Generations-Associated Target Antigens and Indications 15
Table 2: CAR-T Cells Therapy Collaborations and Deal Year, 2015 19
Table 3: CAR-T Cells Therapy collaboration Deals and Values, 2015 20
Table 4: Companies CAR-T Investment for future developments, 2015 22
Table 5: CAR-T Cells Therapy Acquisitions and Deal Year, 2015 24
Table 6: Companies open for licensing and collaborations, 2015 27
Table 7: Number of Products under Development, 2015 28
Table 8: Number of Products under Development by Companies, 2015 29
Table 9: Number of Products under Development by Indication, 2015 31
Table 10: Number of Products Targeting CD19 Antigen, 2015 35
Table 11: Number of Products Targeting Other Antigens, 2015 36
Table 12: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2015 37
Table 13: CAR T-cell Companies and Technologies, 2015 39

List of Figures
Figure 1: Companies Collaborations vs. Financial year, 2015 18
Figure 2: Number of Companies Collaborations, 2015 18
Figure 3: Collaborations and future Profits (In million, $), 2015 21
Figure 4: Number of Products under Development, 2015 28
Figure 5: Number of Products under Development by Companies, 2015 29
Figure 6: Number of Products under Development by Indication, 2015 31
Figure 7: CAR-T cell Targeted Antigens (%), 2015 34
Figure 8: Number of Products Targeting CD19 antigen by Phase, 2015 34
Figure 9: Number of CAR-T Ongoing Clinical Trials & Completion Year, 2015 37
Figure 10:CAR T-cell Companies and Technologies, 2015 39